Noven Pharmaceuticals Inc. (NOVN1)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Nathan Stasko
Employees:
48
4105 HOPSON ROAD, MORRISVILLE, NC 27560
919-485-8080

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Novan, Inc. is a late-stage pharmaceutical company, which focuses on redefining the standard of care in dermatology through the development and commercialization of innovative therapies using the it's nitric oxide platform. It has two key components of nitric oxide platform: Proprietary Nitricil Technology and Topical Formulation Science. The Proprietary Nitricil Technology drives the creation of new chemical entities. The Topical Formulation Science use to modulate or tune product candidates for specific indications. The company was founded by Mark Schoenfisch and Nathan Stasko in 2006 and is headquartered in Durham, NC.

Data derived from most recent annual or quarterly report
Market Cap 410.054 Million Shares Outstanding24.897 Million Avg 30-day Volume 344.053 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.39
Price to Revenue23.0009 Debt to Equity0.0 EBITDA-30.317 Million
Price to Book Value3.8848 Operating Margin-966.8714 Enterprise Value24.08 Million
Current Ratio4.855 EPS Growth0.412 Quick Ratio4.223
1 Yr BETA 0.6496 52-week High/Low 0.0 / Profit Margin-959.6639
Operating Cash Flow Growth20.2286 Altman Z-Score-5.4948 Free Cash Flow to Firm -23.652 Million
View SEC Filings from NOVN1 instead.

View recent insider trading info

Funds Holding NOVN1 (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding NOVN1 BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

YETTER WAYNE P.

  • Director
No longer subject to file 2009-08-27 0

GRANADILLO PEDRO P

  • Director
No longer subject to file 2009-08-27 0

CLARKSON JOHN G

  • Director
No longer subject to file 2009-08-27 0

EISENBERG JEFFREY F EXECUTIVE VICE PRESIDENT

  • Officer
No longer subject to file 2009-08-27 0

SATOW PHILLIP M

  • Director
No longer subject to file 2009-08-27 0

SAVAGE ROBERT G.

  • Director
No longer subject to file 2009-08-27 0

DINH STEVEN M VP & CHIEF SCIENTIFIC OFFICER

  • Officer
No longer subject to file 2009-08-27 0

PRICE MICHAEL DENNIS VP AND CHIEF FINANCIAL OFFICER

  • Officer
No longer subject to file 2009-08-27 0

DENKHAUS DONALD A

  • Director
No longer subject to file 2009-08-27 0

NADER FRANCOIS

  • Director
No longer subject to file 2009-08-27 0

BRANDT PETER C. PRESIDENT AND CEO

  • Officer
  • Director
No longer subject to file 2009-08-27 0

GILBERT RICHARD P. VICE PRESIDENT - OPERATIONS

  • Officer
No longer subject to file 2009-08-27 0

VENDITTI ANTHONY VP - MARKETING AND SALES

  • Officer
No longer subject to file 2009-08-27 0

LIPPMAN JOEL VP AND CHIEF MEDICAL OFFICER

  • Officer
No longer subject to file 2009-08-27 0

OSS CAPITAL MANAGEMENT

SCHAFER BROTHER LLC

SCHAFER OSCAR

GOFFE ANDREW J.

  • 10% Owner
No longer subject to file 2009-03-10 0

BRAGINSKY SIDNEY

  • Director
27,313 2008-06-05 0

WEST COAST ASSET MANAGEMENT INC

LOWE R ATTICUS

HELFERT LANCE W

ORFALEA PAUL J

  • SEE REMARKS BELOWSEE REMARKS BELOWSEE REMARKS BELOWSEE REMARKS BELOW
No longer subject to file 2008-03-14 0

STRAUSS ROBERT C

  • FMR PRESIDENT, CEO & CHAIRMAN
No longer subject to file 2008-01-02 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments